Treatment with CSAT+® increased adiponectin plasma levels (Table 3; p < 0.01) and attenuated the obesity-induced increase in total cholesterol and LDL-c (Table 3; p < 0.05 for both). Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.